Oncotelic Therapeutics (OTCQB: OTLC) has announced the publication of a peer-reviewed study in Biomedicines that demonstrates how its AI-powered PDAOAI platform helped identify a four-gene prognostic signature in hepatocellular carcinoma (HCC), the most common form of liver cancer. The study, published Oct. 23, 2026, used Partitioned Literature Aggregation (PLA), Oncotelic's patented algorithm running on PDAOAI, alongside gene-expression and survival analyses to pinpoint four genes: FKBP1A, EIF4E, RRAGC and PPARGC1A. The signature's association with patient survival was independently validated in a Japanese HCC cohort of 203 patients, strengthening the reliability of the findings.
The identification of this gene signature matters because it supports patient stratification for clinical trials of Sapu003, an intravenous formulation of everolimus that Oncotelic is developing. By using the signature to select patients most likely to respond, the company could improve trial efficiency and increase the chances of success in a cancer with substantial unmet need. The research approach was presented by Oncotelic Chief Business Officer Saran Saund during an Oct. 22 keynote at the 22nd Drug Discovery Strategic Summit in California, highlighting the potential of partitioned AI investigations to uncover testable biological hypotheses and accelerate drug discovery.
Oncotelic plans to expand PDAOAI toward a target scale of approximately 100 billion biological vectors for genetic and protein research. Through its BIO REBOOT initiative, the company also invites researchers and development teams to submit projects for potential funding and support in validation, formulation, regulatory planning and clinical development, subject to scientific review and available resources. This open call could foster collaborations that leverage the platform beyond Oncotelic's internal pipeline.
The announcement is significant for investors and the biotech community because it provides peer-reviewed validation of Oncotelic's AI-driven approach, which could enhance the company's credibility and open new avenues for partnerships. As the company advances its AI platform and drug candidates, stakeholders can follow the latest updates in its newsroom at https://ibn.fm/OTLC. The full press release is available at https://ibn.fm/ctJ4J.
BioMedWire (BMW), a specialized communications platform focused on biotechnology and life sciences, is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions through InvestorWire and other services. For more information, visit www.BioMedWire.com. Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer.
